Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation

Nicola Giuliani1, Simona Colla, Francesca Morandi

  • 1Laboratory of Hematology, Hematology and Bone Marrow Transplantation (BMT) Center, Department of Internal Medicine and Biomedical Science, University of Parma, Parma, Italy. nicola.giuliani@unipr.it

Blood
|June 4, 2005
PubMed

Insights

Multiple myeloma cells inhibit bone formation by suppressing osteoblast development and the key transcription factor RUNX2/CBFA1. This leads to reduced bone in patients, impacting skeletal health.

Area of Science:

  • Bone Biology
  • Hematology
  • Oncology

Background:

  • Multiple myeloma (MM) is characterized by decreased bone formation, leading to osteolytic lesions.
  • The transcription factor RUNX2/CBFA1 is critical for osteoblast differentiation and bone formation.

Purpose of the Study:

  • To investigate how myeloma cells affect osteoblastogenesis.
  • To determine the role of RUNX2/CBFA1 in myeloma-associated bone loss.

Main Methods:

  • Co-culture of human myeloma cells with human osteoblast progenitors.
  • Assessment of osteoblast markers (osteocalcin, alkaline phosphatase, collagen I) and RUNX2/CBFA1 activity.
  • Involvement of cell-to-cell contact and the VLA-4 integrin system were examined.
  • Screening of soluble inhibitors, including IL-7.
  • Analysis of bone marrow biopsies from MM patients.

Main Results:

  • Myeloma cells suppressed osteoblast progenitor formation and differentiation in vitro.
  • Inhibition of osteoblast markers and RUNX2/CBFA1 activity was observed, particularly with cell contact via VLA-4.
  • Interleukin-7 (IL-7) was identified as a potential soluble inhibitor.
  • Reduced numbers of RUNX2/CBFA1-positive cells were found in MM patients with osteolytic lesions.

Conclusions:

  • Myeloma cells directly inhibit osteoblast formation and differentiation.
  • RUNX2/CBFA1 plays a crucial role in the decreased bone formation seen in multiple myeloma.
  • Cell-to-cell contact and IL-7 contribute to this inhibitory process.

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...